Monte Rosa Therapeutics annual stock-based compensation
2020
2021
2022
2023
2024
2025
Monte Rosa Therapeutics Stock-Based Compensation Growth & History (GLUE)
Monte Rosa Therapeutics's stock-based compensation was $18.9M for fiscal 2025.
View full Monte Rosa Therapeutics company overviewMonte Rosa Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $18.9M | $739,000 | +4.08% |
| 2024 | 2024-12-31 | $18.1M | $1.5M | +8.74% |
| 2023 | 2023-12-31 | $16.7M | $5.0M | +42.91% |
| 2022 | 2022-12-31 | $11.7M | $6.5M | +124.31% |
| 2021 | 2021-12-31 | $5.2M | $4.8M | +1368.93% |
| 2020 | 2020-12-31 | $354,000 | — | — |
Monte Rosa Therapeutics quarterly stock-based compensation
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $6.0M | $1.1M | +21.99% |
| Q1 2026 | 2026-03-31 | $5.9M | $651,000 | +12.29% |
| Q4 2025 | 2025-12-31 | $4.3M | −$160,000 | −3.58% |
| Q3 2025 | 2025-09-30 | $4.4M | $82,000 | +1.91% |
| Q2 2025 | 2025-06-30 | $4.9M | $392,000 | +8.71% |
| Q1 2025 | 2025-03-31 | $5.3M | $425,000 | +8.72% |
| Q4 2024 | 2024-12-31 | $4.5M | $395,000 | +9.70% |
| Q3 2024 | 2024-09-30 | $4.3M | −$186,000 | −4.16% |
| Q2 2024 | 2024-06-30 | $4.5M | $349,000 | +8.40% |
| Q1 2024 | 2024-03-31 | $4.9M | $899,000 | +22.62% |
| Q4 2023 | 2023-12-31 | $4.1M | $748,000 | +22.49% |
| Q3 2023 | 2023-09-30 | $4.5M | $1.3M | +39.02% |
| Q2 2023 | 2023-06-30 | $4.2M | $1.3M | +44.55% |
| Q1 2023 | 2023-03-31 | $4.0M | $1.7M | +76.54% |
| Q4 2022 | 2022-12-31 | $3.3M | $1.5M | +79.20% |
| Q3 2022 | 2022-09-30 | $3.2M | $1.1M | +55.04% |
| Q2 2022 | 2022-06-30 | $2.9M | $1.9M | +181.94% |
| Q1 2022 | 2022-03-31 | $2.3M | $2.0M | +793.25% |
| Q4 2021 | 2021-12-31 | $1.9M | — | — |
| Q3 2021 | 2021-09-30 | $2.1M | $2.0M | +4506.67% |
| Q2 2021 | 2021-06-30 | $1.0M | $911,000 | +843.52% |
| Q1 2021 | 2021-03-31 | $252,000 | — | — |
| Q3 2020 | 2020-09-30 | $45,000 | — | — |
| Q2 2020 | 2020-06-30 | $108,000 | — | — |
Monte Rosa Therapeutics stock-based compensation trends
Over the last five fiscal years, Monte Rosa Therapeutics's stock-based compensation increased from $354,000 to $18.9M, a change of $18.5M. The latest reported quarter, Q2 2026, shows $6.0M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Monte Rosa Therapeutics source filings ↗